Galatea Bio, a Miami, FL-based AI-driven genomic research and clinical genetic testing company, raised $25M in funding.
Backers included F-Prime, Helios Digital Ventures, Digitalis Ventures, AME Cloud, CEI Ventures, Alexandria, Founders Collective, Stanford President’s Fund, and HBM Genomics.
The company intends to use the funds to expand its clinico-genomics platform to integrate multi-modal data and AI-driven applications to refine genetic risk analysis for Mendelian and complex diseases, biomarker discovery, and clinical trials optimization.
Founded in 2021 by Carlos D. Bustamante, Ph.D., CEO and President, Galatea Bio is a biotechnology company providing precision medicine through AI-driven data analytics and genomic research on large-scale patient populations, enriched in non-European ancestry. By integrating clinical genomics, a proprietary biobank, and AI-enabled algorithms, it accelerates biomarker and drug target discovery, enhances clinical diagnostics, and supports biopharma partnerships.
FinSMEs
27/03/2025